Cervical cancer

Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer

Friday, September 18, 2020 - 1:30pm

Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.

Key Points: 
  • Balstilimab is a novel anti-PD-1 human monoclonal antibody that has demonstrated promising clinical benefit in second line treatment of cervical cancer.
  • The initiation of the rolling BLA is an exciting step forward for Agenus as we are closer to making our therapies commercially available for patients with cervical cancer who have limited treatment options available, said Dr. Jennifer Buell, President and COO of Agenus.
  • A rolling submission allows Agenus to submit each section of the BLA as it is completed, which enables the FDA to review the submitted sections in parallel with Agenuss completion of the balance of the BLA application.
  • The American Cancer Society estimates around 14,000 new cases of invasive cervical cancer to be diagnosed this year and nearly 4,300 cervical cancer deaths.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Cervical Cancer Market is Expected to Increase With a CAGR of 16.9% for the Study Period of 2017-2030 in 7MM: DelveInsight

Thursday, September 17, 2020 - 3:30pm

An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.

Key Points: 
  • An increase in cervical cancer incidence is also a major reason behind the accelerated momentum of the cervical cancer market size growth.
  • Some of the key insights from cervical cancer market report:
    The incidence of cervical cancer in 7MM (US, UK, Germany, Italy, Spain, France & Japan) in 2020 is expected to be 43,712.
  • Get a cervical cancer sample copy or download a cervical cancer infograph: www.delveinsight.com/sample-request/cervical-cancer-market
    Cervical cancer is a cause of infection from Human papillomavirus (HPV), which can be prevented.
  • The cervical cancer market also homes Merck's star, Keytruda, which got approval in 2018 for advanced cervical cancer for PD-L1 positive patients.

Baum Hedlund Files Gardasil Lawsuit Against Merck on Behalf of Man

Thursday, September 17, 2020 - 12:56am

ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.

Key Points: 
  • ORANGE COUNTY, Calif., Sept. 16, 2020 /PRNewswire/ -- Baum Hedlund Aristei & Goldman filed aGardasil vaccine injury lawsuit today against manufacturer Merck on behalf of a young man who sustained life-altering injuries he alleges were caused by the HPV vaccine.
  • But Merck knew that Gardasil was neither safe nor effective at preventing cervical cancer, and worse, the company knew that Gardasil could cause a host of serious health issues."
  • Baum Hedlund Aristei & Goldmanis one of the nation's leading law firms representing victims who have sustained injuries after receiving the Gardasil HPV vaccine .
  • Since 1973, Baum Hedlund Aristei & Goldman has won over $4 billion in settlements and verdicts on behalf of clients across all areas of practice.

Global Cervical Cancer Market and Competitive Landscape 2016-2019 & 2020-2024 - ResearchAndMarkets.com

Tuesday, September 15, 2020 - 11:11am

The "Global Cervical Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Cervical Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The research report Global Cervical Cancer Market and Competitive Landscape - 2020, provides comprehensive insights into the Cervical Cancer pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Cervical Cancer market size and drug sales.
  • Cervical Cancer pipeline: Find out drugs in clinical trials for the treatment of Cervical Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Cervical Cancer drugs: Identify key drugs marketed and prescribed for Cervical Cancer in the US, including trade name, molecule name, and company
    Cervical Cancer market valuations: Find out the market size for Cervical Cancer drugs in 2019 by countries.

Worldwide Cancer Vaccines Industry to 2027 - Featuring Advaxis, Amgen & Dynavax Technologies Among Others

Tuesday, September 8, 2020 - 4:45pm

Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.

Key Points: 
  • Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.
  • Preventive cancer vaccines are traditional cancer vaccines used in healthy people to prevent cancer.
  • In addition, increase in cancer vaccines usage combined with other therapies, surge in demand for cancer vaccines, the rise in public awareness toward benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines further fuel market growth.
  • By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines.

Global Cancer Vaccines Market (2020 to 2027) - by Technology, Type, Indication and End-user - ResearchAndMarkets.com

Thursday, September 3, 2020 - 5:20pm

Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.

Key Points: 
  • Cancer vaccines are popularly used to treat various types of cancers such as breast cancer, lung cancer, prostate cancer, and cervical cancer.
  • There are two types of vaccines available in market, namely, preventive cancer vaccines and therapeutic cancer vaccines.
  • In addition, increase in cancer vaccines usage combined with other therapies, surge in demand for cancer vaccines, the rise in public awareness toward benefits of cancer vaccines, increase in prevalence of human papilloma virus (HPV) infections, and launch of new cancer vaccines further fuel market growth.
  • By technology, the market is categorized into dendritic cells (DC) cancer vaccines, recombinant cancer vaccines, antigen/adjuvant cancer vaccines, and viral vector & DNA cancer vaccines.

United States Cervical Cancer Industry Analysis 2016-2025: Pipeline, Epidemiology, Drugs, Products, Competition - ResearchAndMarkets.com

Thursday, September 3, 2020 - 12:34pm

The "US Cervical Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Cervical Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • The report provides comprehensive insights into Cervical Cancer pipeline products, Cervical Cancer epidemiology, Cervical Cancer market valuations and forecast, Cervical Cancer drugs sales and competitive landscape in the US.
  • Cervical Cancer pipeline: Find out the products in clinical trials for the treatment of Cervical Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and companies developing the products
    Cervical Cancer drugs: Identify key products marketed and prescribed for Cervical Cancer in the US, including trade name, molecule name, and company
    Cervical Cancer market valuations: Find out the market size for Cervical Cancer drugs in 2019 in the US.
  • Find out how the market advanced from 2016 and forecast to 2025
    Cervical Cancer drugs market share: Find out the market shares for key Cervical Cancer drugs in the US
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Cervical Cancer products

New treatment solution for U.S. cervical cancer patients now available for clinical use

Wednesday, August 19, 2020 - 3:44pm

Worldwide, there are 570,000 thousand new cervical cancer cases each year and 310,000 deaths from previously diagnosed cervical cancers, according to GLOBOCAN 2018 statistics.

Key Points: 
  • Worldwide, there are 570,000 thousand new cervical cancer cases each year and 310,000 deaths from previously diagnosed cervical cancers, according to GLOBOCAN 2018 statistics.
  • With the availability of Geneva, clinicians can now take advantage of a single gynecological applicator to treat most cervical cancer patients via intracavitary and/or interstitial brachytherapy treatment options.
  • "In the United States, Pap and HPV testing have been successful at continuously reducing the incidence of cervical cancer.
  • "Elekta is committed to innovation in the field of cervical cancer brachytherapy, which is a proven technique for improved overall survival.

MobileODT completed $4 million series round C

Wednesday, August 12, 2020 - 1:30pm

TEL AVIV, Israel, Aug. 12, 2020 /PRNewswire/ -- MobileODT , the developer of the EVA System for cervical cancer screening, announced the completion of a $4 million series C fundraising round.

Key Points: 
  • TEL AVIV, Israel, Aug. 12, 2020 /PRNewswire/ -- MobileODT , the developer of the EVA System for cervical cancer screening, announced the completion of a $4 million series C fundraising round.
  • The round will enable MobileODT to further develop an AI (Augmented Intelligence) clinical decision support technology for the evaluation of cervical cancer at the point of care.
  • Globally, 932 million women require cervical cancer screening, yet almost 600 million women will never be tested[2]due to lack of access to healthcare.
  • The company raised $26 million to date from Orbimed, Tristel, Tara Health, Laerdal, DAI, private funds and investors.